|
1
|
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.
|
J Am Coll Cardiol
|
2005
|
1.60
|
|
2
|
Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.
|
Circulation
|
2005
|
1.42
|
|
3
|
C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro.
|
Arterioscler Thromb Vasc Biol
|
2004
|
1.27
|
|
4
|
CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling.
|
J Clin Invest
|
2012
|
1.11
|
|
5
|
Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.
|
Arterioscler Thromb Vasc Biol
|
2006
|
1.07
|
|
6
|
Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products.
|
Diabetes
|
2004
|
1.01
|
|
7
|
Detection of long-term progression of myocardial fibrosis in Duchenne muscular dystrophy in an affected family: a cardiovascular magnetic resonance study.
|
Eur J Radiol
|
2010
|
0.89
|
|
8
|
Ivabradine reduces chemokine-induced CD4-positive lymphocyte migration.
|
Mediators Inflamm
|
2010
|
0.89
|
|
9
|
Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers.
|
Arterioscler Thromb Vasc Biol
|
2005
|
0.89
|
|
10
|
Proinflammatory effects of C-Peptide in different tissues.
|
Int J Inflam
|
2012
|
0.87
|
|
11
|
Vascular effects of PPARgamma activators - from bench to bedside.
|
Prog Lipid Res
|
2007
|
0.85
|
|
12
|
Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes.
|
Cell Mol Life Sci
|
2010
|
0.85
|
|
13
|
Myocardial scar extent evaluated by cardiac magnetic resonance imaging in ICD patients: relationship to spontaneous VT during long-term follow-up.
|
Int J Cardiovasc Imaging
|
2010
|
0.84
|
|
14
|
C-peptide: a new mediator of atherosclerosis in diabetes.
|
Mediators Inflamm
|
2012
|
0.82
|
|
15
|
C-peptide promotes lesion development in a mouse model of arteriosclerosis.
|
J Cell Mol Med
|
2012
|
0.81
|
|
16
|
Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study.
|
Diab Vasc Dis Res
|
2010
|
0.81
|
|
17
|
C-Peptide and atherogenesis: C-Peptide as a mediator of lesion development in patients with type 2 diabetes mellitus?
|
Exp Diabetes Res
|
2008
|
0.79
|
|
18
|
Vitamin C supplement use may protect against gallstones: an observational study on a randomly selected population.
|
BMC Gastroenterol
|
2009
|
0.77
|
|
19
|
Blood oxygen level-dependent magnetic resonance imaging using T2-prepared steady-state free-precession imaging in comparison to contrast-enhanced myocardial perfusion imaging.
|
Int J Cardiol
|
2009
|
0.77
|
|
20
|
Cardiac involvement in juvenile overlap-myositis detected by cardiac magnetic resonance imaging.
|
Int J Cardiol
|
2010
|
0.77
|
|
21
|
C-peptide induces human renal mesangial cell proliferation in vitro, activating Src-kinase, PI-3 kinase and ERK1/2.
|
Mol Cell Endocrinol
|
2012
|
0.76
|
|
22
|
Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension.
|
Diabetes Res Clin Pract
|
2010
|
0.76
|
|
23
|
Clinical results of single and multiple bioresorbable drug-eluting scaffolds for treatment of de-novo coronary artery disease.
|
Coron Artery Dis
|
2016
|
0.75
|
|
24
|
Percutaneous Mitral Valve Repair With the MitraClip in Primary Compared With Secondary Mitral Valve Regurgitation Using the Mitral Valve Academic Research Consortium Criteria.
|
J Invasive Cardiol
|
2017
|
0.75
|
|
25
|
Neoplastic pericardial effusion induces functional nonvalvular mitral valve stenosis.
|
J Am Coll Cardiol
|
2010
|
0.75
|